Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

Gut

Volumn 44, Issue 5, 1999, Pages 625-628

  Neurath, M F ^a   Wanitschke, R ^a   Peters, M ^a   Krummenauer, F ^a   Meyer Zum Buschenfelde K H ^a   Schlaak, J F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Azathioprine; Crohn's disease; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANEMIA; ARTICLE; CHOLESTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SCORING SYSTEM;

EID: 0033003888     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.5.625     Document Type: Article

References (28)

1. 1 Strober W, Fuss I, Kelsall B, et al. Mucosal immune regulation and dysregulation: the pathogenesis of inflammatory bowel disease. In: Sleisinger MH, ed. Gastrointestinal disease. Pathophysiology, diagnosis, management. Update 4. WB Saunders, 1996:1-10.
2. 2 Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-8.
3. 3 Kornbluth A, Salomon P, Sachar DB. Crohn's disease. In: Sleisinger MH, ed. Gastrointestinal disease. Pathophysiology, diagnosis, management. Update 4. WB Saunders, 1996: 1270-304.
4. 4 Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to IL-12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1280-9.
5. 5 Fuss I, Neurath MF, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphocyte secretion profiles in inflammatory bowel disease. J Immunol 1996;157:1261-70.
6. 6 Breese E, MacDonald TT. TNF-alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol 1995;371B:821-4.
7. 7 Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
8. 8 Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;122:132-42.
9. 9 Present DH, Meltzer SJ, Krumholz MP, et al. 6 mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989;111: 641-9.
10. 10 Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-9.
11. 11 Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996;10:77-84.
12. 12 Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
13. 13 Hildner K, Märker-Hermann E, Schlaak JF, et al. Azathioprine and mycophenolate mofetil specifically modulate cytokine production by murine T cells. Ann N Y Acad Sci (in press).
14. 14 Neurath MF, Hildner K, Becker C, et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in collagen-induced arthritis. A mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol (in press).
15. 15 European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-5.
16. 16 Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11:S117-19.
17. 17 Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997;350:494.
18. 18 Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis. J Am Acad Dermatol 1987;17:962-71.
19. 19 Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med 1980;302:981-7.
20. 20 Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;ii:1273-6.
21. 21 O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;ii:955-7.
22. 22 Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-19.
23. 23 Sachar DB. Budesonide for inflammatory bowel disease: is it a magic bullet? N Engl J Med 1994;331:873-4.
24. 24 Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332: 292-7.
25. 25 Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
26. 26 Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113:383-9.
27. 27 Farthing MJG, Newcombe RG. Reporting of clinical trials in Gut: the CONSORT statement. Gut 1997;40:563-4.
28. 28 Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil in chronic active inflammatory bowel disease - a preliminary report. FALK Symposia 1998;105:A40